KCT0002229尚未招募未知
The influence of patient-clinician interaction context on acupuncture outcomes in functional dyspepsia - a randomized controlled international multi-center trial
Kyung Hee University Oriental Medical Center0 个研究点目标入组 59 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •(1) Age between 20 and 65 years
- •(2) Meeting the definition of Functional Dyspepsia(FD) and Postprandial distress syndrome (PDS) as a subtype of Functional Dyspepsia according to the Rome III criteria
- •(3) Complaints of a degree of dyspepsia more than 40 points on the visual analogue scale (VAS; 0, no symptom at all; 100, the most severe symptom one has ever had)
- •(4) Individuals who agreed not to take any other new treatments associated with Functional Dyspepsia during the study
- •(5) Individuals who voluntarily agreed and singed informed consent form
排除标准
- •(1) Have abnormal esophagogastroduodenoscopy results recently or evidence of any organic diseases affecting gastrointestinal tract (e.g. erosive esophagitis, peptic ulcer, dysplasia, mucosa-associated, lymphoid tissue lymphoma, esophageal cancer, gastric cancer)
- •(2) Individuals who have apparent signs of irritable bowel syndrome
- •(3) Individuals who have alarmingsymptoms (weight loss, black or tarry stool, or dysphagia)
- •(4) Individuals who have serious structural organ diseases (diseases of the heart, lung, liver, or kidney) or mental illness
- •(5) Individuals who have undergone surgery related to the gastrointestinal tract (except for appendectomy performed for more than 6 months ago)
- •(6) Individuals who are pregnant or breastfeeding
- •(7) Individuals who are taking drugs that could affect the gastrointestinal tract ; a minimum wash-out period of 2 weeks is required before participating in the trial.
- •(8) Individuals who have participated other clinical trial within 1 month from the present
- •(9) Individuals who are positive for human immunodeficiency virus infection
- •(10) Individuals who are taking herbal medicine or oriental remedy that associated with dyspepsia / drugs that are considered inappropriate for this study
- •(11) Difficulties in attending the trial (e.g., paralysis, serious mental illness, dementia, drug addiction, time constraints, severe disorder of vision or hearing, illiteracy, etc.)
- •** Patients who have severe depression will be excluded from the study (One who has more than 24 points in Beck Depression Inventory) [12].
- •(12) Individuals with other issues that could interfere with acupuncture treatment (e.g., clotting disorders or leukopenia, a pacemaker, epilepsy, or anticoagulant therapy)
- •** To exclude patients with severe organic disease, following blood and urine test will be performed at screening visit: Complete Blood Count (White Blood Cell, Hemoglobin, Hematocrit, Platelet), Liver Function Test (AST, ALT, rGT), Renal Function Test (BUN, Creatinine), ESR, Cholesterol (Total Cholesterol, HDL Cholesterol, LDL Cholesterol, TG), Glucose, Routine Urine Analysis
研究者
相似试验
尚未招募
1 期
Impact of doctor-patient participation in medical decision-making model on acupuncture combined with medicine for hearing rehabilitation in patients with sudden deafnessITMCTR2000003476Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
已完成
不适用
Patient perception and clinical effectiveness of an allogeneic cortical sheet versus an autologous laminated bone graft for the treatment of horizontal bone defectsISRCTN58672316ThinkingPerio Research - Periocentrum Bilbao15
已完成
不适用
Application of patient communication software in conscious patients under mechanical ventilatioConscious patients under mechanical ventilation.Difficulty or need for assistance with communicationQF22IRCT20220315054293N1Mashhad University of Medical Sciences60
已完成
不适用
Involving medical companions in an explanation about switching to a biosimilar.Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for rheumatic diseases.Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for dermatological diseases.Decision makingInflammatory and Immune System - Rheumatoid arthritisSkin - Dermatological conditionsPublic Health - Health service researchACTRN12619001435178Professor Keith Petrie79
已完成
2 期
Investigating the association between clinical and ocular characteristics with the outcomes of corneal collagen cross-linking (CXL)Keratoconus.H18.6KeratoconusIRCT20131229015975N4Esfahan University of Medical Sciences85